Omnicell (NASDAQ:OMCL) Rating Increased to Hold at Zacks Research

Omnicell (NASDAQ:OMCL) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Omnicell’s Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

A number of other research analysts have also recently weighed in on OMCL. Benchmark raised their price target on Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price for the company in a report on Wednesday, January 7th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Finally, Wells Fargo & Company upped their price target on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.50.

Omnicell Stock Performance

OMCL opened at $37.48 on Tuesday. The stock has a market cap of $1.70 billion, a P/E ratio of 937.23, a P/E/G ratio of 1.40 and a beta of 0.79. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The stock’s 50 day simple moving average is $44.18 and its 200 day simple moving average is $38.44. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analyst estimates of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, equities analysts anticipate that Omnicell will post 1.09 EPS for the current fiscal year.

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares in the last quarter. Empowered Funds LLC increased its position in Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after purchasing an additional 4,866 shares in the last quarter. Jane Street Group LLC raised its holdings in Omnicell by 201.5% in the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after buying an additional 109,382 shares during the period. Finally, Penserra Capital Management LLC raised its holdings in Omnicell by 264.2% in the second quarter. Penserra Capital Management LLC now owns 9,215 shares of the company’s stock valued at $270,000 after buying an additional 6,685 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.